CVS Health (CVS) Tops Q1 EPS by 28c, Maintains FY EPS Guidance

CVS Health (NYSE: CVS) reported Q1 EPS of $1.91, $0.28 better than the analyst estimate of $1.63. Revenue for the quarter came in at $66.8 billion versus the consensus estimate of $64.06 billion.

GUIDANCE:

CVS Health sees FY2020 EPS of $7.04-$7.17, versus the consensus of $7.04.

• GAAP diluted EPS guidance range of $5.47 to $5.60 and Adjusted EPS (2) guidance range of $7.04 to $7.17 remain unchanged
• Cash flow from operations guidance range of $10.5 billion to $11.0 billion remains unchanged
• Given the likelihood of significant variability in the impact of COVID-19 on the Company's financial statement line items and related ratios, 2020 additional detailed guidance not noted above is withdrawn

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• CVS Health (CVS) PT Raised to $110 at BofA Securities